Orphan Drug Regulation: A missed opportunity for children and adolescents with cancer
- 1 October 2017
- journal article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 84, 149-158
- https://doi.org/10.1016/j.ejca.2017.07.021
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- From class waivers to precision medicine in paediatric oncologyThe Lancet Oncology, 2017
- Asfotase alfa therapy for children with hypophosphatasiaJCI Insight, 2016
- Worldwide collaboration for orphan drug designationNature Reviews Drug Discovery, 2016
- The Orphan Drug ActAmerican Journal of Clinical Oncology, 2016
- The influence of the European paediatric regulation on marketing authorisation of orphan drugs for childrenOrphanet Journal of Rare Diseases, 2014
- Childhood cancer survival in Europe 1999–2007: results of EUROCARE-5—a population-based studyThe Lancet Oncology, 2013
- Need for change in implementation of paediatric regulationThe Lancet Oncology, 2013
- Is the European Pediatric Medicine Regulation Working for Children and Adolescents with Cancer?Clinical Cancer Research, 2013
- New drugs for children and adolescents with cancer: the need for novel development pathwaysThe Lancet Oncology, 2013
- European regulation on orphan medicinal products: 10 years of experience and future perspectivesNature Reviews Drug Discovery, 2011